Pauline Trinh

Pauline Trinh

Auto-generated profile, based on publicly available information

Pauline Trinh

Department of Epidemiology, Columbia University, New York, New York, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2018 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
PTPauline Trinh
Pauline Trinh
JZJesse R. Zaneveld
Jesse R. Zaneveld
SSSarah Safranek
Sarah Safranek
PRPeter M. Rabinowitz
Peter M. Rabinowitz
The One Health concept stresses the ecological relationships between human, animal, and environmental health. Much of the One Health literature to date has examined the transfer of pathogens from animals (e.g., emerging zoonoses) and the environment to humans. The recent rapid development of technology to perform high throughput DNA sequencing has expanded this view to include the study of entire microbial communities. Applying the One Health approach to the microbiome allows for consideration of both pathogenic and non-pathogenic microbial transfer between humans, animals, and the environment. We review recent research studies of such transmission, the molecular and statistical methods being used, and the implications of such microbiome relationships for human health. Our review identified evidence that the environmental microbiome as well as the microbiome of animals in close contact can affect both the human microbiome and human health outcomes. Such microbiome transfer can take place in the household as well as the workplace setting. Urbanization of built environments leads to changes in the environmental microbiome which could be a factor in human health. While affected by environmental exposures, the human microbiome also can modulate the response to environmental factors through effects on metabolic and immune function. Better understanding of these microbiome interactions between humans, animals, and the shared environment will require continued development of improved statistical and ecological modeling approaches. Such enhanced understanding could lead to innovative interventions to prevent and manage a variety of human health and disease states.

1 January 2017 in Science of The Total Environment
Verified
Journal Article
Open access
EEElise G. Elliott
Elise G. Elliott
PTPauline Trinh
Pauline Trinh
XMXiaomei Ma
Xiaomei Ma
BLBrian P. Leaderer
Brian P. Leaderer
MWMary H. Ward
Mary H. Ward
NDNicole Deziel
Nicole Deziel
The widespread distribution of unconventional oil and gas (UO&G) wells and other facilities in the United States potentially exposes millions of people to air and water pollutants, including known or suspected carcinogens. Childhood leukemia is a particular concern because of the disease severity, vulnerable population, and short disease latency. A comprehensive review of carcinogens and leukemogens associated with UO&G development is not available and could inform future exposure monitoring studies and human health assessments. The objective of this analysis was to assess the evidence of carcinogenicity of water contaminants and air pollutants related to UO&G development. We obtained a list of 1177 chemicals in hydraulic fracturing fluids and wastewater from the U.S. Environmental Protection Agency and constructed a list of 143 UO&G-related air pollutants through a review of scientific papers published through 2015 using PubMed and ProQuest databases. We assessed carcinogenicity and evidence of increased risk for leukemia/lymphoma of these chemicals using International Agency for Research on Cancer (IARC) monographs. The majority of compounds (>80%) were not evaluated by IARC and therefore could not be reviewed. Of the 111 potential water contaminants and 29 potential air pollutants evaluated by IARC (119 unique compounds), 49 water and 20 air pollutants were known, probable, or possible human carcinogens (55 unique compounds). A total of 17 water and 11 air pollutants (20 unique compounds) had evidence of increased risk for leukemia/lymphoma, including benzene, 1,3-butadiene, cadmium, diesel exhaust, and several polycyclic aromatic hydrocarbons. Though information on the carcinogenicity of compounds associated with UO&G development was limited, our assessment identified 20 known or suspected carcinogens that could be measured in future studies to advance exposure and risk assessments of cancer-causing agents. Our findings support the need for investigation into the relationship between UO&G development and risk of cancer in general and childhood leukemia in particular.

1 August 2016 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JWJoshua Z. Willey
Joshua Z. Willey
MGMichael V. Gavalas
Michael V. Gavalas
PTPauline N. Trinh
Pauline N. Trinh
MYMelana Yuzefpolskaya
Melana Yuzefpolskaya
AGA. Reshad Garan
A. Reshad Garan
PCPaolo C. Colombo
Paolo C. Colombo

1 April 2018 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
LTLauren K. Truby
Lauren K. Truby
AGA. Reshad Garan
A. Reshad Garan
RGRaymond C. Givens
Raymond C. Givens
KTKoji Takeda
Koji Takeda
HTHiroo Takayama
Hiroo Takayama
VTVeli K. Topkara
Veli K. Topkara
Background: Continuous-flow left ventricular assist devices (CF-LVADs) have become a standard treatment choice in advanced heart failure patients. We hypothesized that practice patterns with regards to CF-LVAD utilization vary significantly among transplant centers and impact waitlist outcomes. Methods and Results: The United Network for Organ Sharing registry was queried to identify adult patients who were waitlisted for heart transplantation (HT) between 2008 and 2015. Each patient was assigned a propensity score based on likelihood of receiving a durable CF-LVAD before or while waitlisted. The primary outcomes of interest were death or delisting for worsening status and HT at 1 year. A total of 22 863 patients from 92 centers were identified. Among these, 9013 (39.4%) were mechanically supported. CF-LVAD utilization varied significantly between and within United Network for Organ Sharing regions. Freedom from waitlist death or delisting was significantly lower in propensity-score–matched patients who were mechanically supported versus medically managed (83.5% versus 79.2%; P <0.001). However, cumulative incidence of HT was also lower in mechanically supported patients (53.3% versus 63.6%; P <0.001). Congruous mechanical and medical bridging strategies based on clinical risk profile were associated with lower risk of death or delisting (hazard ratio, 0.88; P =0.027) and higher likelihood of HT (hazard ratio, 1.14; P <0.001). Conclusions: CF-LVAD utilization may lower waitlist mortality at the expense of lower likelihood of HT. Decision to use CF-LVAD and timing of transition should be individualized based on patient-, center-, and region-level risk factors to achieve optimal outcomes.

19 November 2010 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
SDSienmi Du
Sienmi Du
FSFrancisco Sandoval
Francisco Sandoval
PTPauline Trinh
Pauline Trinh
EUElizabeth Umeda
Elizabeth Umeda
RVRhonda Voskuhl
Rhonda Voskuhl
Estrogens act upon nuclear estrogen receptors (ER) to ameliorate cell‐mediated autoimmune disease. As most immunomodulatory effects of estrogens in EAE have been attributed to the function of ER‐α, we previously demonstrated that ER‐β ligand treatment reduced disease severity without affecting peripheral cytokine production or levels of CNS inflammation, suggesting a direct neuroprotective effect; however, the effect of ER‐β treatment on the function of immune cells within the target organ remained unknown. Here, we used adoptive transfer studies to show that ER‐β ligand treatment was protective in the effector, but not the induction phase of EAE, as shown by decreased clinical disease severity with the preservation of axons and myelin in spinal cords. The analysis of the immune cell infiltrates in the CNS revealed that while ER‐β ligand treatment did not reduce overall levels of CNS inflammation, there was a decrease in the DC percentage, and these CNS DC had decreased TNF‐α production. Finally, experiments using DC deficient in ER‐β revealed that the expression of ER‐β on DC was essential for protective effects of ER‐β ligand treatment in EAE. Our results demonstrate for the first time an effect of ER‐β ligand treatment in vivo on DC in the target organ of a prototypic cell‐mediated autoimmune disease.

1 June 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JAJordan E. Axelrad
Jordan E. Axelrad
APAlberto Pinsino
Alberto Pinsino
PTPauline N. Trinh
Pauline N. Trinh
ATAnusorn Thanataveerat
Anusorn Thanataveerat
CBChristian Brooks
Christian Brooks
MYMelana Yuzefpolskaya
Melana Yuzefpolskaya